Used in pharmaceutical synthesis as a chiral intermediate for developing kinase inhibitors, particularly in oncology research. Its structure supports selective binding to protein targets involved in cell signaling pathways, making it valuable in the design of active pharmaceutical ingredients for treating cancers. The compound’s fluorinated and brominated aromatic systems enhance its metabolic stability and binding affinity. It is also employed in structure-activity relationship (SAR) studies to optimize drug potency and selectivity.